Projects

Lonza Houston’s Biotech Facility, Pearland, Texas

In April 2018, viral and cell therapy manufacturer Lonza Houston completed constructing a new biotech facility for immunotherapy development and manufacturing in Pearland, Texas, US.

Project Type
Biotech Facility
Location
Pearland, Texas, US
Start of Construction
March 2016
Opened
April 2018
Total Floor Space
300,000ft2 (27,870m2)
Developer
Lonza Group

In April 2018, viral and cell therapy manufacturer Lonza Houston completed constructing a new biotech facility for immunotherapy development and manufacturing in Pearland, Texas, US.

The City of Pearland and the Pearland Economic Development Corporation’s (PEDC) approved the project’s construction in December 2015. The build fulfils the city’s long-lasting goal of establishing a broad spectrum of medical and life sciences organisation in the region.

“The new biotech facility fulfils the city’s long-lasting goal of establishing a broad spectrum of medical and life sciences organisation in the region.”

A ground-breaking ceremony was held on March 2016 for the project, which was attended by Pearland’s Mayor Tom Reid, city manager Clay Pearson, state representative Ed Thompson, Lonza Houston’s site director Ricardo Jimenez, Lonza’s operations for emerging technologies senior vice-president (SVP) Stefan Troger, and the PEDC board chair Rushi Patel and board members Reid Wendell, Brandon Dansby and Lucy Stevener.

The facility was officially opened in April 2018.

Lonza’s biotech facility details

The state-of-the-art facility is located on an 11-acre site on Kirby Drive in Pearland’s Lower Kirby District. It has a total floor space of 300,000ft2 (27,870m2) and is designed to accommodate office spaces, a process development unit, quality control laboratories and av fully segregated fill-and-finish suite.

The facility contains independent modular cleanrooms with a total capacity of up to 2,000l-scale production in single-use bioreactors.

The cleanrooms were designed to manufacture cell therapy products to meet the growing demand in the US and European markets. The facility doubles the company’s current capacity for the production of viral gene and virally modified therapeutics.

The facility initially generated more than 80 jobs and is expected to create more than 200 opportunities by the end of 2018 in the fields of administration, manufacturing, process development and quality assurance.

Lonza built the new biotech facility in collaboration with Pinchal & Co, Creed Commercial Development, ARCO Design/Build, and CRB.

Marketing commentary on Lonza

Lonza is a global leader and trusted supplier in the pharma, biotech and speciality ingredients markets. Headquartered in Basel, Switzerland, the company is focused on advanced manufacturing, high-quality control systems, regulatory expertise, and research and development (R&D) capabilities.

The company’s products and services include active pharmaceutical ingredients (API), stem cell therapies, drinking water sanitisers, vitamin B compounds, organic personal care ingredients, industrial preservatives and microbial control solution to combat viruses, bacteria and other dangerous pathogens.

The company also provides agricultural services and products.

Related Projects